drugset / Trial / NCT07610733
Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, prospective, randomized controlled, phase II study. The primary objective is to evaluate the effect of endocrine therapy modification (switching from a 3-month to a 1-month GnRHa) versus continuation of the 3-month GnRHa on E2 control at 3 months in young patients with hormone receptor-positive breast cancer and iOFS.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-09-01
- Completion
- 2030-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Goserelin | Other / unclassified | 3.6 mg | — |
| Subject | Goserelin | Other / unclassified | 10.8 mg | — |
| Subject | Leuprolide | Other / unclassified | 3.75 mg | — |
| Subject | Leuprolide | Other / unclassified | 11.25 mg | — |
| Background | Tamoxifen | Small molecule | — | — |